Welcome to medac in the United Kingdom.

medac GmbH is a privately owned German company founded in 1970. medac mainly promotes the development and marketing of the therapeutics in the field of oncology and autoimmune diseases.
Here in the UK we endeavour to provide the best quality pharmaceutical products with faultless service in an effective, timely and customer-focused manner.



Metoject Injectable Methotrexate

Find out more about Metoject »

medac EULAR Satellite Symposium 2016

What are the current best-practice strategies using subcutaneous
methotrexate in rheumatoid arthritis? Has the value of methotrexate as anchor drug changed in the age
of biologicals and biosimilars? What is known about the effects and mechanisms conveyed by
methotrexate (MTX) on the cardiovascular system? How can rheumatologists influence patient
These current topics in the field of rheumatology will be covered by this year’s EULAR satellite
symposium held by medac, the world-wide leading provider of subcutaneous methotrexate.
“We are very much looking forward to the symposium,” states Heiner Will, Managing Director of
medac. “Especially due to the participation of the former ACR president, Dr. Stanley Cohen, United
States, who is going to share his expertise on subcutaneous methotrexate in daily practice. It has been
published that MTX remains frequently under-dosed1; but nevertheless the potential of subcutaneous
methotrexate improving RA therapy is increasingly recognized and applied in practice.”
The topic of methotrexate in the age of biosimilars and biologic drugs will be outlined by well-known
Prof. Jürgen Braun, Germany. He had conducted the ground-breaking clinical trial showing that the
parenteral MTX was more effective than the oral administration2. Usually, MTX increases the
effectiveness of biologic agents in rheumatoid arthritis3, and also its advantageous cost-effectiveness
persist in the presence of biosimilars4.
The important aspects of patient adherence or non-adherence to therapy and the role of the
rheumatologists are going to be discussed by Prof. Johanna Hazes, the Netherlands. Her publications
stress the value of open and trustworthy relationships between rheumatologists and patients5. Good
Press Release
09.06.2016 Page 2 / 3
relationships may enable discussing non-adherence issues and thus help the patient to focus on the
treatment goal.
Another important highlight of the symposium will be the input provided by Prof. Evgeny Nasonov,
Russian Federation, who is going to present recent insights in the cardioprotective mechanism of
MTX6. The inflammatory events of RA are known to contribute to cardiovascular risk factors. Various
hypothetical mechanisms will be discussed how methotrexate deploys its cardioprotective effects.
2.507 characters (spaces included)
1 O'Dell JR et al., Arthritis Rheumatol. 2015; 67 (suppl 10): ACR 2015 Abstract Number 1997
2 Braun J et al., Arthritis Rheum 2008;58:73-81
3 Nam JL et al., Ann Rheum Dis 2010;69:976-986
4 Fitzpatrick R et al., Clin Rheumatol. 2013;32:1605-1612
5 Pasma A et al., Arthritis Res Ther 2015;17:281
6 Popkova TV et al., Curr Med Chem 2015; 22:1903-1910
For further info please contact Media Spokesperson Volker Bahr (see below).
Press Contact
Media Spokesperson
Volker Bahr
Tel. +49 (0)4103 – 8006 558
Fax +49 (0)4103 – 8006 8934
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
22880 Wedel
medac Gesellschaft für klinische Spezialpräparate mbH
medac is a privately held German pharmaceutical company located in Wedel, Tornesch and Hamburg. Medicinal products
from medac support doctors and patients throughout the world in overcoming their acute and persistent diseases in the
indication areas of oncology & haematology, urology and autoimmune disorders. In addition, medac develops and markets
Press Release
09.06.2016 Page 3 / 3
special diagnostic test systems. Since 1970, medac has been committed to unifying therapeutic and diagnostic agents under
one roof.
You can find further information on the company and its products on the internet under www.medac.de.

At this years symposium in London this June, International experts will share experiences on MTX therapy, biosimilars, cardioprotective effects and patient adherence

Click here for more information.


Find your nearest autoimmune or oncology representative

There are medac representatives all over the UK on hand to provide you with the information you need.


Find your nearest representative »